Bubs Australia (ASX:BUB) confirmed that it formally lodged its new infant formula submission with the US Food and Drug Administration (FDA) to cover all three of its infant milk formulas, goat, 365 day grass fed, and essential, which are all currently sold in the US market, according to a Monday Australian bourse filing.
The firm said that it is expected that the regulator will immediately commence its formal review of Bubs' submission.
By the end of the second quarter of the fiscal year, Bubs enrolled a total of 478 infants over 16 months, completing its infant enrollment for the US clinical trial. The firm has been conducting the large-scale clinical trial as part of its commitment to obtain permanent regulatory approval in the US market.
Its shares rose 4% in recent trading on Monday, reaching their highest point in over 52 weeks.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.